What is the issue size of Molbio Diagnostics Ltd IPO?

The issue size of the Molbio Diagnostics Ltd IPO is yet to be announced.

What is 'pre-apply' for Molbio Diagnostics Ltd IPO?

Pre-apply will allow you to apply for the Molbio Diagnostics Ltd IPO 4 days before the subscription period starts.

If I pre-apply for Molbio Diagnostics Ltd IPO, when will my order get placed?

Your order will be placed on the exchange as soon as the Molbio Diagnostics Ltd IPO bidding starts. You will receive a UPI request within 24 hours after the bidding period opens.

When will I know if my Molbio Diagnostics Ltd IPO order is placed?

We will notify you when your Molbio Diagnostics Ltd IPO order is placed with the exchange.

What are the open and close dates of the Molbio Diagnostics Ltd IPO?

Molbio Diagnostics Ltd IPO will be open between 10 Aug '26 and 12 Aug '26.

What is the lot size and minimum order quantity of the Molbio Diagnostics Ltd IPO?

Molbio Diagnostics Ltd IPO lot size is 18 and minimum order quantity is 252.

What is the allotment date for the Molbio Diagnostics Ltd IPO?

Molbio Diagnostics Ltd IPO allotment date is 13 Aug '26.

Is Molbio Diagnostics stock good for long term?

Based on our AI analysis, Molbio Diagnostics has a financial score of N/A/100 and a market potential score of N/A/100.

What is the lot size of Molbio Diagnostics stock?

Use the ViewIPO Lot Size Calculator to instantly find the exact lot size and maximum investment limits for Retail, sHNI, and bHNI categories for Molbio Diagnostics.

Molbio Diagnostics Share Price & Stock Analysis

Name: Molbio Diagnostics Stock
Brand: Molbio Diagnostics
Rating: 3.8 (1 reviews)

Home›India›Molbio Diagnostics ()

Molbio DiagnosticsNSE / BSE:

Analyzed by ViewIPO Financial Research Team

Medical Devices & DiagnosticsIndia•Filed 2026-08-10•Listed 2026-08-17•Size Pending Data

The total amount of money the company is trying to raise from the public through this IPO.

•Lot Size 18

The minimum number of shares an investor must bid for in an IPO.

•Listing Price ₹923

The estimated or final price at which the shares will start trading on the stock exchange.

Listing Return

The percentage gain or loss on the listing day compared to the original IPO issue price.

₹173.02 (+21.44%)

Live Subscription

How many times the IPO has been demanded by investors. E.g., 10x means investors want 10 times more shares than available.

70.05x Total

Check Allotment

Status Link

Is Molbio Diagnostics a Good Stock? Quick Verdict

Molbio Diagnostics IPO scored 55/100 (High Risk) in our deep analysis. The strongest pillar is Dilution at 60/100, while Financial is the primary concern at 48/100. Molbio Diagnostics presents a compelling investment case with strong financial growth, innovative technology platform, and strategic expansions, though transparency around IPO proceeds and issue size remains a concern.

Stock Score

55/100

High Risk

Quick Verdict

Revenue grew 72.8% from FY24 to FY26, reaching ₹1,445.69 crore in FY26

PAT increased 96.5% from FY24 to FY26, reaching ₹164.14 crore in FY26

Truenat platform offers testing for 30 diseases through 43 assays as of March 31, 2026

Issue size and total IPO proceeds amount are not disclosed in the prospectus

General corporate purposes allocation in IPO proceeds is unspecified

Company Snapshot

Revenue (TTM)

Total money brought in by the company's operations before deducting any expenses.

₹1445.7Cr↑ -18.02% YoY

Profitability

The company's total profit after all expenses, taxes, and costs have been deducted.

PositiveNet Income ₹8.35Cr

Gross Margin

The percentage of revenue remaining after subtracting the direct costs of producing the goods sold.

65.4%

Market Cap

The total value of all the company's shares combined. It shows the overall size of the company.

₹36CrAt upper band ₹807

Issue Size

—

Industry

Medical Devices & Diagnostics

P/E Ratio

Price-to-Earnings. How much you pay for ₹1 of company profit. A high P/E might mean the stock is expensive.

17.9xValuation Multiple

Return on Equity

Return on Equity. Shows how efficiently the company generates profit using the shareholders' money.

15.59%Profitability

EPS

Earnings Per Share. The portion of a company's profit allocated to each individual share of stock.

₹14.56Earnings Per Share

NAV

Net Asset Value. The total value of the company's assets minus its liabilities, divided by the number of shares.

₹101.51Net Asset Value

RoNW

Return on Net Worth. Similar to RoE, it measures the profitability against the net worth of the company.

14.55%Return on Net Worth

Risk Breakdown

Governance

Moderate

Financial

Expensive

Valuation

Expensive

Competition

Expensive

Dilution

Moderate

Promoter / Mgmt

Moderate

AI Summary

Molbio Diagnostics Ltd is a point-of-care diagnostics company that develops and manufactures diagnostic technologies for infectious and non-communicable diseases. Its main product is the Truenat platform, a portable molecular diagnostics system that offers molecular testing for 30 diseases through 43 assays. The company has a dedicated R&D setup with a sizable scientific team and a track record of product development. It has also expanded into radiology and digital pathology through acquisitions.

Overall Verdict: Molbio Diagnostics presents a compelling investment case with strong financial growth, innovative technology platform, and strategic expansions, though transparency around IPO proceeds and issue size remains a concern.

Key Highlights

•The company's Truenat platform offers molecular testing for 30 diseases through 43 assays.
•The platform can process one, two, or four samples simultaneously.
•The company has a portable, battery-operated molecular diagnostics platform designed for point-of-care use.
•The company has a dedicated R&D setup with a sizable scientific team and a track record of product development.
•The company has expanded into radiology and digital pathology through acquisitions.

Financial Performance

Revenue (Annual)
Total money brought in by the company's operations before deducting any expenses.

↑ +41.7% YoY

INR in Crores

Net Income (Annual)
The company's total profit after all expenses, taxes, and costs have been deducted.

↑ +20.2% YoY

INR in Crores

Gross Margin (Annual)
The percentage of revenue left after paying for direct costs of goods sold over the year.

↑ +65.4% Delta

In Percentage

EBITDA vs PAT
Earnings Before Interest, Taxes, Depreciation, and Amortization. Shows pure operating performance.

EBITDA YoY

INR in Crores

EBITDA

PAT

Listing Timeline

IPO Opens2026-08-10

IPO Closes2026-08-12

Basis of Allotment2026-08-13

Refunds & Demat2026-08-14

Listing Date2026-08-17

Valuation Analysis

Issue Price₹807

Estimated Fair Value

The theoretical true worth of the company based on its financial performance and peers.

Pending Data

Valuation Premium

How much more expensive this IPO is compared to its estimated fair value or its industry peers.

Pending

vs Fair Value

Stock DNA

Growth

Evaluates the company's historical and projected revenue and profit expansion.

Governance

Assesses the quality, transparency, and track record of the company's management team.

Profitability

Measures how effectively the company turns its sales into actual profit.

Valuation

Analyzes whether the IPO price is cheap, fair, or expensive compared to peers.

Competition

Evaluates the company's market share, moats, and competitive threats in its industry.

Execution

Assesses the company's ability to successfully utilize IPO proceeds and deliver on its promises.

Pros vs Cons

Pros

Proprietary Truenat platform enables multi-disease point-of-care molecular testing in resource-limited settings in approx. 60 minutes.
Consistent double-digit revenue growth with top-line reaching ₹1,445.69 crore in FY26.
Solid profitability with steady PAT increase from ₹83.54 crore in FY24 to ₹164.14 crore in FY26.
Strong intellectual property barrier with 16 patents in India and 191 patents across foreign jurisdictions.
Dedicated internal R&D capabilities through subsidiary Bigtec Private Limited backed by 136 scientists.

Cons

Concentration of revenue dependent on Truenat platform devices and consumable test kit sales.
Operational and integration risks following recent acquisitions in radiology (Prognosys) and digital pathology (OptraScan).
Dependency on maintaining stringent regulatory approvals and patent protection across global markets.

Institutional Signals

Anchor Investors

Large institutional investors who buy shares before the IPO opens to the public, signaling confidence.

Undisclosed

Molbio Diagnostics IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

Molbio Diagnostics Stock — Frequently Asked Questions

View Report

View All Active & Upcoming Stocks & IPOs View Stock & IPO Calendar

Market Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to Sauda ASBA Offer for Sale (OFS)

View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another stock or IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Molbio Diagnostics

What is the expected listing price of Molbio Diagnostics?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Molbio Diagnostics on our Live GMP Tracker.

Molbio Diagnostics Share Price & Stock Analysis

Quick Answers

Key Stock Information

ViewIPO AI Analysis Score

Frequently Asked Questions

What is the issue size of Molbio Diagnostics Ltd IPO?

What is 'pre-apply' for Molbio Diagnostics Ltd IPO?

If I pre-apply for Molbio Diagnostics Ltd IPO, when will my order get placed?

When will I know if my Molbio Diagnostics Ltd IPO order is placed?

What are the open and close dates of the Molbio Diagnostics Ltd IPO?

What is the lot size and minimum order quantity of the Molbio Diagnostics Ltd IPO?

What is the allotment date for the Molbio Diagnostics Ltd IPO?

Molbio DiagnosticsNSE / BSE:

Is Molbio Diagnostics a Good Stock? Quick Verdict

Quick Verdict

Company Snapshot

Risk Breakdown

AI Summary

Key Highlights

Financial Performance

Revenue (Annual) Total money brought in by the company's operations before deducting any expenses.

Net Income (Annual) The company's total profit after all expenses, taxes, and costs have been deducted.

Gross Margin (Annual) The percentage of revenue left after paying for direct costs of goods sold over the year.

EBITDA vs PAT Earnings Before Interest, Taxes, Depreciation, and Amortization. Shows pure operating performance.

Listing Timeline

Valuation Analysis

Stock DNA

Pros vs Cons

Pros

Cons

Institutional Signals

Molbio Diagnostics IPO Reddit Pulse & Sentiment

No Public Data Available

Molbio Diagnostics Stock — Frequently Asked Questions

Related Stock Reports

German Green Steel and Power

Orient Cables

AceVector

Sai Urja Indo Ventures

Runwal Enterprises

Market Terminology Explained

Want to analyze another stock or IPO?

Frequently Asked Questions about Molbio Diagnostics

Is Molbio Diagnostics stock good for long term?

What is the lot size of Molbio Diagnostics stock?

What is the expected listing price of Molbio Diagnostics?

Revenue (Annual)
Total money brought in by the company's operations before deducting any expenses.

Net Income (Annual)
The company's total profit after all expenses, taxes, and costs have been deducted.

Gross Margin (Annual)
The percentage of revenue left after paying for direct costs of goods sold over the year.

EBITDA vs PAT
Earnings Before Interest, Taxes, Depreciation, and Amortization. Shows pure operating performance.